hemophilia B


Also found in: Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to hemophilia B: Hemophilia C, Von Willebrand disease
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.hemophilia B - a clotting disorder similar to hemophilia A but caused by a congenital deficiency of factor IX
bleeder's disease, haemophilia, hemophilia - congenital tendency to uncontrolled bleeding; usually affects males and is transmitted from mother to son
References in periodicals archive ?
Hemophilia B is expected to grow at a rapid rate of over 6% during the forecast period.
Hemophilia B is an inherited bleeding disorder caused by a defect in the F9 gene, which encodes instructions for making the factor IX protein that helps blood clot.
According to the company, REBINYN is indicated for on-demand treatment and control of bleeding episodes and the perioperative management of bleeding in adults and children with hemophilia B.
Visit Hemophilia Treatment Market by Drug Type (Antifibrinolytic Agents, Desmopressin, Plasma Derived Coagulation Factor Concentrates - Factor VIII, Factor IX, Combination, Recombinant Coagulation Factor Concentrates - Factor VIII, Factor IX, Combination), Indication Type (Acquired Hemophilia, Hemophilia A, Hemophilia B, Hemophilia C), and Distribution Channel (E-commerce, Hospital Pharmacies, Retail Pharmacies) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/hemophilia-treatment-market/
In this case report, the difficulties in treatment of an infant with severe hemophilia B who developed antibody and allergic reaction against FIX treatment have been discussed.
* Early identification of canine hemophilia A, hemophilia B and von Willebrand disease (VWD), a severe bleeding defect.
INTRODUCTION: The X-linked inherited coagulation disorders, hemophilia A (Factor VIII deficiency) and hemophilia B (factor IX deficiency), together with Von Willebrand disease comprise 95 to 97 percent of all the inherited deficiencies of coagulation factors.1, 2 Both factors take part in the intrinsic pathway of blood coagulation and affected individuals have severe, moderate and mild forms of disease, defined by factor plasma levels of <1%, 2-5%, and 6-40%.respectively.
IB1001 is an intravenous recombinant Factor IX (rFIX) being developed for the treatment and prevention of bleeding episodes in hemophilia B. The IB1001 development program includes pharmacokinetic, safety, and efficacy data from a Phase III trial in people with hemophilia B.
Hemophilias A and B are X-linked genetic disorders; hemophilia A is due to deficiency of clotting factor VIII, while hemophilia B is due to deficiency of clotting factor IX.
Most patients with hemophilia A are dependent on factor VIII replacement therapy, while patients with hemophilia B are dependent on factor IX replacement therapy.
Arthropathy was the most frequently developing complication in patients 10 (100%) of severe Hemophilia B. Post circumcision bleeding was found to be the most common first episode of bleeding in patients of haemophilia B 29 (64.4%).